Learn about BYETTA, the BYETTA Pen. in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components. Patient Information Leaflet. Package leaflet: Information for the patient. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution . Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Byetta (Exenatide).
|Published (Last):||6 December 2017|
|PDF File Size:||14.41 Mb|
|ePub File Size:||12.31 Mb|
|Price:||Free* [*Free Regsitration Required]|
If pancreatitis is suspected, BYETTA should be discontinued promptly and should not be restarted if pancreatitis is confirmed. The most common side effects byetta package insert BYETTA include nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, acid stomach, constipation, and weakness.
You may give other people a serious infection, or get a serious infection from them.
Official BYETTA® (exenatide) injection Healthcare Professional Website
Inflammation of the pancreas pancreatitis may happen, which may be severe and lead to death. Increased risk of hypoglycemia when used byetta package insert combination with a sulfonylurea SU or when used with a glucose-independent insulin secretagogues eg, meglitinides.
Use in pediatric patients is not recommended as safety and effectiveness have not been established. To report drug exposure during pregnancy call Call your healthcare provider right away if byetta package insert have nausea, vomiting, or diarrhea that will not go away, or if you cannot take liquids by mouth.
Should not be used in patients with severe renal impairment or end-stage renal disease. Talk to your byetta package insert provider first if you are breastfeeding or plan to breastfeed. When used with insulin, evaluate and consider reducing the insulin dose in patients at increased risk of hypoglycemia. Staying Active Learn how regular physical activity can help you manage type 2 diabetes.
If byetts of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy. No placebo-treated patients withdrew due to nausea or vomiting.
Because exenatide is commonly associated with gastrointestinal adverse reactions, BYETTA is not recommended in patients with severe gastrointestinal disease eg gastroparesis.
BYETTA should not be used in people with type 1 diabetes or people with diabetic ketoacidosis a condition caused by very high blood sugar. You are encouraged to report negative side byetta package insert of prescription drugs to the FDA. Use paxkage twice-daily exenatide in basal insulin—treated patients with type 2 diabetes: Pen-sharing poses byetta package insert risk for transmission of blood-borne pathogens, even if the needle is changed.
Postmarketing reports of altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, byetta package insert requiring hemodialysis and kidney transplantation.
After initiation and dose increases of BYETTA, observe patients carefully for pancreatitis including persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting.
This site is intended for US Consumers.
FDA Internet Application Site (Accessdata) Error
byetta package insert BYETTA is an injectable prescription medicine that may improve blood sugar glucose control in adults with type 2 diabetes, when used with diet and exercise.
AstraZeneca provides this link as a service to website visitors.
All other trademarks are property of their respective owners. Patients may develop antibodies to exenatide. This product information is intended for US Byetta package insert Professionals only. Your risk for getting low blood sugar hypoglycemia is higher if you take BYETTA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin.
Use with caution with medications that have a narrow therapeutic index or require rapid gastrointestinal absorption. You may report side effects related to AstraZeneca products by clicking here. Tell your healthcare provider if you have severe problems with your stomach, packaeg as delayed emptying of your stomach gastroparesis or problems with digesting food. No clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA or any byetta package insert antidiabetic drug.
byetta package insert
The Double B logo is a trademark of the AstraZeneca group of companies. Postmarketing reports of serious hypersensitivity reactions eg anaphylaxis and angioedema. Byetta package insert reports of increased international normalized ratio INR sometimes associated with bleeding with concomitant use of warfarin. Not a substitute for insulin and should not be used in patients with type 1 diabetes or diabetic ketoacidosis.
Based on animal data, BYETTA may cause fetal harm and should be used during byetta package insert only if the potential benefit justifies the potential risk to the fetus.